Forward-looking organizations use real-world data long before a product reaches commercialization.
If you’re a clinical operations leader, the pressure to design and execute efficient trials has never been higher. Timelines are tight, patient populations are hard to access, and regulatory expectations continue to evolve. In this environment, real-world evidence (RWE) is becoming increasingly critical—not just in the later phases of development or for market access, but valuable in the earliest stages of clinical research.
Traditionally, RWE has been associated with post-market surveillance, market access, or health economics studies. But forward-looking organizations are using real-world data (RWD)—such as electronic health records, claims databases, patient registries, and even wearable/device data—long before a product reaches commercialization.
Leveraging RWE in the early phases offers several advantages for Biotechs to maximize product development efforts with limited resources.
Optimize Trial Design and Feasibility
Early access to real-world patient data helps clinical operations teams understand the natural history of a condition, typical care pathways, and treatment patterns. This insight sharpens inclusion/exclusion criteria, helps avoid overly restrictive protocols, and allows teams to gauge the actual availability of eligible patients. In short, RWE increases the likelihood of a trial that is both feasible and efficient.
Find the Best Sites and Patients for Your Study
Site activation and patient recruitment remain top challenges for clinical operations leaders. By analyzing RWD, companies can identify high-performing sites with the right patient populations and experience. They can also better predict recruitment bottlenecks and address them proactively. This evidence-driven approach helps reduce costly delays in trial start-up and enrollment.
Showcase Clinical Benefits with Regulators and Payers
Understanding how diseases are managed in routine practice can reveal which endpoints matter most to clinicians and patients—linking trial data with real-world data with a more holistic approach to patient care. RWE uncovers real-world outcomes that align with meaningful clinical benefit and resonate with regulators and payers. For clinical ops teams, this translates into more relevant endpoints and higher confidence in trial success.
De-risk Early Investment Decisions
By incorporating real-world insights early, you can make smarter go/no-go decisions before committing significant resources to large-scale trials. RWE provides an evidence base that validates assumptions, highlights unmet needs, clarifies where a therapy can have the most impact, and, most importantly, market viability of the product
Build a Foundation for Future Regulatory and Market Discussions
Early integration of RWE lays the groundwork for regulatory submissions and payer negotiations later on. Agencies like the FDA and EMA are increasingly open to RWE as a supplement to traditional clinical trial data. For clinical operations leaders, this means their early-stage planning directly contributes to smoother downstream regulatory and reimbursement processes.
Launch RWE without Overhauling Existing Processes
Incorporating RWE early doesn’t mean overhauling existing processes. Instead, it’s about building small but impactful bridges between real-world data sources and trial operations. A few ways to accomplish this are:
- Working with a vendor that has expertise in multiple data sources helps to drive the most impactful information.
- Using feasibility studies informed by real-world patient populations to generate information to meet your business use case.
- Creating minimally viable abstracts, manuscripts, and publications tailored to your regulatory, investor, or market access goals.
- Partnering with vendors that specialize in disease-specific RWD that matches your product development goals.
Creative Ways to Gain RWE Expertise
As an emerging Biotech, your RWE needs are likely sporadic and don’t require a full-time resource. Instead of training your team or trying to hire an FTE, there are creative ways to gain RWE expertise and reap the benefits.
With CHEORS powered by BioBridges, we’re able to partner with your company to provide project-based deliverables or fractional consultants. These alternative ways of gaining expertise allow you to focus on your core business without missing the important benefits of RWE early in product development.
Final Thoughts
For clinical operations leaders, the promise of RWE in early development is not optional—it’s a practical way to design smarter studies, accelerate timelines, and position therapies for long-term success. Those who integrate RWE early gain a competitive edge: fewer surprises, better patient engagement, and trials that are designed with the realities of clinical practice in mind.